“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial of panobinostat for Hodgkin lymphoma that has come back after a stem cell transplant or has not responded to treatment
This trial looked at a drug called panobinostat for people with Hodgkin lymphoma. It was open to people whose Hodgkin lymphoma had come back after high dose chemotherapy and a stem cell transplant, or had not responded to this treatment.
More about this trial
Doctors may use chemotherapy and radiotherapy to treat Hodgkin lymphoma. Some people have high dose chemotherapy followed by a stem cell transplant. Researchers are trying to find treatments that will help people who have Hodgkin lymphoma that doesn’t respond or comes back after having this type of standard treatment.
Panobinostat is a drug that blocks
Research in the laboratory had shown that panobinostat could stop Hodgkin lymphoma cells growing. The main aims of this trial were to
- Find out if panobinostat helped people with Hodgkin lymphoma that had come back after a stem cell transplant
- Learn more about the side effects
Summary of results
The trial team found that panobinostat could help people with Hodgkin lymphoma that had come back after a stem cell transplant.
This trial recruited 129 people. Everyone had panobinostat.
Of the 96 people whose Hodgkin lymphoma had responded
- For 5 people there was no sign of their lymphoma (a
- For 30 people their lymphoma had shrunk (a
The average amount of time it took for their lymphoma to come back or get worse was just under 6 months.
The most common side effects reported were
- A drop in blood cells causing an increased risk of infection, bruising and bleeding
- Diarrhoea or constipation
- Feeling or being sick
- Loss of appetite and taste changes
- Muscle spasms
The trial team concluded panobinostat can help people with Hodgkin lymphoma who had already had a stem cell transplant. They also found out more about the side effects of panobinostat.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor John Radford
Experimental Cancer Medicine Centre (ECMC)